Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
28.86
-0.34 (-1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Dyne Therapeutics to Present at November Investor Conferences
November 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
October 30, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at October Investor Conferences
September 28, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Shares of Dyne Therapeutics Fell This Week
September 15, 2023
Insiders sold more than 15,000 shares of company stock on Tuesday.
Via
The Motley Fool
Dyne Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Dyne Therapeutics
March 03, 2023
Via
Benzinga
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 25, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 17, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
May 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
May 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday
April 04, 2023
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
March 23, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
March 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
March 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
February 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
February 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
February 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 07, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
January 26, 2023
Via
Benzinga
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
December 15, 2022
Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.
Via
Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
December 14, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
November 23, 2022
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.